Adjunctive Smart Phone Based Smoking Cessation Treatment
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Descrizione dettagliata
Research Supporting Study Objectives. Tobacco use is the leading cause of preventable death in the U.S. Over 443,000 deaths per year are attributable to smoking, with the leading causes of smoking-attributable death being cancer, cardiovascular diseases, and respiratory disease. Although the prevalence of smoking has declined to 20.6% among U.S. adults, 31.1% of those living in poverty are currently smoking. Numerous studies have shown that low SES and financial strain are associated with a reduced likelihood of smoking cessation. As such, lung cancer incidence is far greater among those with low education and who are living in poverty, relative to their higher SES counterparts. Although individuals of low SES are just as likely to attempt smoking cessation, they are less likely to succeed. As such, smoking cessation interventions for low SES populations have had limited success (e.g., biologically confirmed 7-day point prevalence abstinence rates of 7-13% at 6-month follow-up. Innovative smoking cessation interventions are needed to help reduce the rate of smoking in socioeconomically disadvantaged populations of smokers.
Ecological Momentary Assessment and Smoking Cessation Treatments. To date, most studies that have examined smoking and smoking cessation in socioeconomically disadvantaged smokers have used focus groups or traditional lab/clinic based assessment methodology. In the latter scenario, study participants arrive at a lab or clinic for their baseline visit and are asked to answer questions about their "average" or "recent" (e.g., over the past 2 weeks) mood, level of stress, and smoking urges. Participants return to the lab/clinic for follow-up visits and are asked to report thoughts, feelings, and activities that occurred weeks or even months earlier (e.g., "How stressed were you when you smoked your first cigarette after your quit date?"). This type of assessment methodology may result in biased and/or inaccurate estimates due to recall biases and errors in memory and only offers a gross understanding of how cessation symptoms effect smoking lapses and relapse. A more nuanced picture of these symptoms may offer important insights that may be used to create or improve cessation interventions for socioeconomically disadvantaged smokers, who face unique and substantial challenges in quitting smoking.
Ecological momentary assessment (EMA), in which handheld devices (e.g., smart phones) are used to capture moment to moment experience, is currently the most accurate way to measure phenomena in real time in natural settings. EMAs are often used to assess individuals at multiple time points throughout a day. Thus, momentary changes in key variables can be tracked and potentially used to initiate novel interventions. EMA research may facilitate a better understanding of the mechanisms involved in successful cessation attempts, those affecting smoking lapses, and those implicated in the transition from lapse to relapse. Although multiple studies have identified momentary predictors of smoking relapse to our knowledge, no studies have used a participant's responses to EMAs to automatically prompt tailored smoking cessation interventions. Using smart phones to detect high relapse risk situations and automatically deliver tailored smoking cessation treatments may help socioeconomically disadvantaged smokers quit.
Tipo di studio
Tipo di studio
Iscrizione (Effettivo)
Iscrizione
Fase
Fase
- Non applicabile
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
Participants will be included in the study if they:
- earn a score greater than or equal to 4 on the Short REALM indicating greater than 6th grade English literacy level,
- are willing to quit smoking 7 days from their first visit,
- are greater than or equal to 18 years of age,
- have an expired CO level greater than or equal to 8 ppm suggestive of current smoking,
- are currently smoking greater than or equal to 5 cigarettes per day,
- are willing and able to attend 6 weekly sessions (i.e., week -1, quit day, week +1, week +2, week +3, week +4) and the 12 week follow-up session , and
- have not previously participated in Project PREVAIL [STU 042011-096] at Parkland Hospital. Please note that the Parkland smoking cessation program (usual care) is currently offered in English only.
Exclusion Criteria:
Participants will be excluded from the study if they:
- are unwilling to quit smoking 7 days from their first visit,
- have already quit smoking,
- earn a score less than 4 on the Short REALM indicating less than or equal to 6th grade literacy level,
- produce an expired CO level less than 8 ppm,
- are currently smoking less than 5 cigarettes per day,
- are unwilling or unable to attend 7 assessment sessions,
- are less than 18 years of age, and/or
- have not previously participated in Project PREVAIL [STU 042011-096] at Parkland Hospital. Please note that the Parkland smoking cessation program (usual care) is currently offered in English only.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Altro
- Assegnazione: N / A
- Modello interventistico: Assegnazione di gruppo singolo
- Mascheramento: Nessuno (etichetta aperta)
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Study Visits
The Short form of the Rapid Estimate of Adult Literacy in Medicine (REALM) will be administered to ensure that all participants are able to read at > sixth grade level. Expired carbon monoxide (CO) will be measured. Assessment: Participants will complete self-report questionnaires; and expired CO, weight, and height will be measured. Participants will be provided with a Samsung Galaxy Light Android smart phone and instructed on how to: 1) use the phone features, 2) complete EMAs, and 3) use the adjunctive Smart-T phone based treatment. Participants will receive 4 random prompts and 1 daily diary prompt during their normal waking hours each day for three consecutive weeks. Random assessments will take approximately 1 min to complete and daily diary assessments will take approximately 5 mins to complete. |
The Samsung Galaxy Light Smart phone uses the Android 4.2 operating system.
The phone has a 4.0 inch (480x800-pixel resolution) touch screen display, a built in microphone, earphone jack, audio speaker, and a rechargeable battery with 12.5 hours of talk time.
The phone has 4G and is Wi-Fi and GPS capable.
Participants navigate through the EMA program and enter data simply by touching the screen, similar to a pen-and-paper questionnaire.
Thus, computer/typing skills are not required.
Participants have the ability to call and receive calls from research staff through the smart phone free of charge.
All phones will be equipped with Global Positioning Systems (GPS) capability.
The smart phones are also equipped with a Secure Digital card to store data as it is collected.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Smoking abstinence
Lasso di tempo: 12 weeks
|
Evidence of abstinence from smoking confirmed by questionnaire.
|
12 weeks
|
Collaboratori e investigatori
Sponsor
Sponsor
Investigatori
Investigatori
- Investigatore principale: Jennifer Gonzalez, UT Southwestern Medical Center
Studiare le date dei record
Studia le date principali
Inizio studio
Inizio studio
Completamento primario (Effettivo)
Completamento primario
Completamento dello studio (Effettivo)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- SCCC-PSO1Z14
- STU 012014-012 (Altro identificatore: UTSouthwestern Medical Center)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Cancro ad alto rischio
-
NCT07139769Reclutamento
-
NCT07266025Non ancora reclutamentoAdenocarcinoma gastrico | Adenocarcinoma gastroesofageo | Immunoterapia | Mismatch Repair Deficient o MSI-High Tumori Solidi
-
NCT07259473Non ancora reclutamentoImmunoterapia | Mismatch Repair Deficient o MSI-High Tumori Solidi | Adenocarcinoma della giunzione gastrica/gastroesofagea
-
NCT02101411CompletatoPRU (unità di reattività piastrinica) | APT (terapia antipiastrinica) | HOTPR (High on Treat Platelet Reactivity)
-
NCT01208103CompletatoAdenocarcinoma dell'intestino tenue | Adenocarcinoma dell'intestino tenue in stadio III AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIA AJCC v8 | Adenocarcinoma dell'intestino tenue in stadio IIIB AJCC v8 | Adenocarcinoma dell'intestino tenue stadio IV AJCC v8 | Ampolla di Vater Adenocarcinoma | Stadio III Ampolla di Vater Cancer AJCC v8 | Stadio IIIA Ampolla di Vater Cancer AJCC v8 | Stadio IIIB Ampolla di Vater Cancer AJCC v8 | Stadio IV Ampolla di Vater Cancer AJCC v8
-
NCT06669325CompletatoNausea e vomito postoperatori (PONV) | PUNTEGGIO APFEL RISK
-
NCT06022705CompletatoNausea, Postoperatorio | Vomito, Postoperatorio | PUNTEGGIO APFEL RISK
-
NCT01261520CompletatoStudio delle donne cinesi che non hanno aderito alle linee guida per lo screening mammografico dell'American Cancer Society
-
NCT07625735Non ancora reclutamentoMismatch Repair Deficient o MSI-High Tumori Solidi | Metastasi linfonodali | Adenocarcinoma della giunzione gastrica/gastroesofagea | Lymphatic Invasion
-
NCT06928987Attivo, non reclutanteQualità della vita al lavoro | Professionisti paramedici | Toccare Massaggio | Cancer Center
Prove cliniche su Smart Phone Based Smoking Cessation
-
NCT05026580RitiratoDolore | Artrosi, ginocchio | Osteoartrite, anca | Qualità della vita correlata alla salute | Funzione
-
NCT05693571Iscrizione su invitoDepressione | Lupus Eritematoso, Sistemico
-
NCT01473550CompletatoDisturbo dell'umore | Disturbo psicotico
-
NCT02046993CompletatoIpertensione | Pressione sanguigna
-
NCT07506538Attivo, non reclutanteOsteoporosi primaria
-
NCT04223570CompletatoTerapia fotodinamica | Protoporfirina IX